The Prognostic Value of $^{18}$F-FDG PET/CT and KRAS Mutation in Colorectal Cancers

Kolorektal Kanserlerde $^{18}$F-FDG PET/CT ve KRAS Mutasyonunun Prognostik Değeri

**Objective:** Prognostic effect of KRAS mutation and side of tumor in colorectal cancer is a highly controversial subject. Therefore, we evaluated the association between FDG uptake pattern in $^{18}$F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) imaging and KRAS mutation and tumor localization in patients with a diagnosis of colon cancer and assessed the effects of these three factors on prognosis and survival.

**Methods:** Eighty-three patients with colorectal cancer were retrospectively included in this study. $^{18}$F-FDG PET/CT study was performed for pretreatment staging. The maximum standardized uptake value (SUV$_{\text{max}}$) of the primary tumor and survival data of patients were compared between groups. KRAS mutations were detected with the help of real-time Polymerase Chain Reaction technique through genomic DNA extracted from paraffin-embedded tumor tissue blocks. Tumor lesions with potential KRAS mutations were classified as mutant KRAS and wild type.

**Results:** Twenty-five patients were female while 58 were male. The mean age of the patients was 59.8±11.3 years. Mean follow-up was 35.5±18.9 months. Primary tumor was localized in the left colon in 83.1% of patients and in the right colon in 16.9%. KRAS mutation was detected in 54.2% (n=45) of patients. Mean SUV$_{\text{max}}$ of patients with primary tumor was estimated to be 21.1±9.1 (range= 6.0-47.5). Mean tumor SUV$_{\text{max}}$ of patients with a KRAS mutation (24.0±9.0) was found to be significantly higher than those without KRAS mutation (17.7±8.2) (p=0.001). Mean survival was significantly shorter in patients with locoregional nodal metastasis than in patients without locoregional nodal metastasis as well as in patients with distant nodal metastasis and in patients with organ metastasis in initial PET/CT than in patients without organ metastasis. Also, mean survival was nearly statistically-significantly shorter in patients with tumors located in left colon (34.2±19.4) than in right colon (43.2±14.6) (p=0.059). However, we found no significant impact of KRAS mutation on survival.

**Conclusion:** In our study, we found that tumor localization had no significant effect on prognosis in patients with colon cancer. On the other hand, FDG uptake was observed to be higher in the presence of KRAS mutation and it was concluded that coexistence of KRAS mutation with higher SUV$_{\text{max}}$ is a negative prognostic factor.

**Keywords:** Colorectal cancer, KRAS mutation, $^{18}$F-fluoro-deoxy-glucose positron emission tomography/computerized tomography ($^{18}$F-FDG PET/CT), prognosis

**Abstract**

Objective: Prognostic effect of KRAS mutation and side of tumor in colorectal cancer is a highly controversial subject. Therefore, we evaluated the association between FDG uptake pattern in $^{18}$F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography ($^{18}$F-FDG PET/CT) imaging and KRAS mutation and tumor localization in patients with a diagnosis of colon cancer and assessed the effects of these three factors on prognosis and survival.

Methods: Eighty-three patients with colorectal cancer were retrospectively included in this study. $^{18}$F-FDG PET/CT study was performed for pretreatment staging. The maximum standardized uptake value (SUV$_{\text{max}}$) of the primary tumor and survival data of patients were compared between groups. KRAS mutations were detected with the help of real-time Polymerase Chain Reaction technique through genomic DNA extracted from paraffin-embedded tumor tissue blocks. Tumor lesions with potential KRAS mutations were classified as mutant KRAS and wild type.

Results: Twenty-five patients were female while 58 were male. The mean age of the patients was 59.8±11.3 years. Mean follow-up was 35.5±18.9 months. Primary tumor was localized in the left colon in 83.1% of patients and in the right colon in 16.9%. KRAS mutation was detected in 54.2% (n=45) of patients. Mean SUV$_{\text{max}}$ of patients with primary tumor was estimated to be 21.1±9.1 (range= 6.0-47.5). Mean tumor SUV$_{\text{max}}$ of patients with a KRAS mutation (24.0±9.0) was found to be significantly higher than those without KRAS mutation (17.7±8.2) (p=0.001). Mean survival was significantly shorter in patients with locoregional nodal metastasis than in patients without locoregional nodal metastasis as well as in patients with distant nodal metastasis and in patients with organ metastasis in initial PET/CT than in patients without organ metastasis. Also, mean survival was nearly statistically-significantly shorter in patients with tumors located in left colon (34.2±19.4) than in right colon (43.2±14.6) (p=0.059). However, we found no significant impact of KRAS mutation on survival.

Conclusion: In our study, we found that tumor localization had no significant effect on prognosis in patients with colon cancer. On the other hand, FDG uptake was observed to be higher in the presence of KRAS mutation and it was concluded that coexistence of KRAS mutation with higher SUV$_{\text{max}}$ is a negative prognostic factor.

Keywords: Colorectal cancer, KRAS mutation, $^{18}$F-fluoro-deoxy-glucose positron emission tomography/computerized tomography ($^{18}$F-FDG PET/CT), prognosis

**ÖZ**

Amaç: Kolorektal kanserde KRAS mutasyonu ve tümörün lokalizasyonu ile ilişkili prognostik etki tartışmalı bir konudur. Bu nedenle $^{18}$F-floroo-2-deoksiglukoz pozitron emisyon tomografi/bilgisayarlı tomografi ($^{18}$F-FDG PET/CT) görüntülemede FDG tutulum paterni ile kolon kanseri tanısı almış hastalarda KRAS mutasyonu ve tümör lokalizasyonu arasındaki ilişkiyi değerlendik. Bu üç faktörün prognoz ve sağkalım üzerindeki etkileri değerlendirildi. KRAS mutasyonları, parafin

**Address for Correspondence:** Esra Arslan MD, University of Health and Sciences, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey
**Phone:** +90 212 459 64 55  **E-mail:** dresraarslan@gmail.com  **ORCID ID:** orcid.org/0000-0002-9222-8883
**Received:** 23.09.2019  **Accepted:** 11.11.2019

©Copyright 2020 by Turkish Society of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy published by Galenos Yaynevi.
KRAS allele, the mutant p21 and pulmonary malignancies. As a result of deleted KRAS mutated oncogene associated with pancreatic, colorectal growth factor receptor (7). KRAS is the most commonly that regulate cell growth and apoptosis via endothelial and NRAS) codes membrane-bound G proteins (p21 RAS) colorectal cancers (5). The RAS gene family (KRAS, HRAS environmental risk factors increase the transformation into genetic mutations along with the accumulation of factors (5,6). It is well known that a group of prominent and adjuvant chemotherapy methods are also prognostic metastases alter the prognosis in colon cancer. In addition, Stage, grade, presence of obstruction and/or perforation and presence of vascular invasion, nodal and organ metastases alter the prognosis in colon cancer. In addition, RAS mutation, surgical intervention, radiation therapy and adjuvant chemotherapy methods are also prognostic factors (5,6). It is well known that a group of prominent genetic mutations along with the accumulation of environmental risk factors increase the transformation into colorectal cancers (5). The RAS gene family (KRAS, HRAS and NRAS) codes membrane-bound G proteins (p21 RAS) that regulate cell growth and apoptosis via endothelial growth factor receptor (7). KRAS is the most commonly mutated oncogene associated with pancreatic, colorectal and pulmonary malignancies. As a result of deleted KRAS allele, the mutant p21 KRAS is activated and induces cell proliferation. Therefore, studies have recently concentrated on KRAS-targeted therapies (8).

It is difficult to establish the association between prognosis and treatment options in patients with colorectal cancer. Heterogeneous survival data are reported even in patients with same pathological grade. Therefore, establishing the prognostic factors accurately is vital in determining high risk patients (9). However, certain contexts are still controversial for prognosis. For example, there are contradictory prognosis and survival data published on right and left colon which arise from different anatomical and embryonic origins (10). The findings of studies that evaluate right and left colon difference along with the presence of RAS mutation are particularly limited and controversial (11). Therefore, in our study, we evaluated FDG uptake pattern in patients who were initially staged with 18 F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging, which is increasingly used in the diagnosis, staging and prognosis determination of various types of cancer, and the presence of KRAS mutation and the association of tumor localization with these two factors and questioned the prognostic power and survival impact of these associations.

Materials and Methods

Patients

Eighty-three patients with colorectal cancer who had staging and follow-up 18F-FDG PET/CT examinations and tumor specimen for mutation analysis between September 2012 and June 2018 were included in this retrospective study. Histopathologic diagnosis and 18F-FDG PET/CT imaging were obtained prior to surgical resection and/or chemotherapy/radiation therapy. The study was approved by the Istanbul Training and Research Hospital Local Ethics Committee (no: 2018/1228). The diagnosis and histopathologic analysis of primary colorectal cancer were verified with materials obtained by surgery or from the biopsy. Staging was performed according to Tumor, Node and Metastases (TNM) staging system for colon cancer in concordance with the American Joint Committee on Cancer Guidelines (12).
**18F-FDG PET/CT Imaging**

In our study, primary lesions were assessed according to the location (left or right colon), 18F-FDG uptake and the presence of lymph node and distant metastases in PET/CT. Patients whose blood glucose levels were below 150 mg/dL after six hours of fasting were suitable for the procedure. Sixty minutes after the intravenous injection of 3.7-5.2 MBq/kg 18F-FDG, PET/CT imaging was obtained from vertex to upper femur (Biograph mCT ultra HD LSO PET/CT; Siemens Molecular Imaging; Hoffman Estates, IL, USA). CT imaging for PET/CT was performed using a multi-detector scanner with 20 slices, at 80-140 kV, 20-266 mAs, 0.8 pitch and 512x512 matrix [personalized settings determined by automatic exposure control system; automatically defined by the software used by manufacturer (CareDose 4D) depending on the patient and region assessed]. CT imaging was performed between vertex and upper-thigh in craniocaudal direction with 5 mm of slice thickness and 0.5 seconds of rotation time. Then, PET imaging was performed in the same range through craniocaudal direction at 8 to 9 bed positions, 1.5 minutes for each PET bed using LSO PET scanner. Ultra HD images were acquired using time of flight (TOF) + true X algorithm at iteration 2 and subset 16 values for reconstruction.

Standardized uptake value (SUV\text{max}) was calculated by drawing a region of interest (ROI) around the region with the highest 18F-FDG uptake. SUV\text{max} was calculated automatically by the software using the following formula: maximum activity within ROI (MBq/mL) /injected 18F-FDG dose (MBq/kg).

**Mutation Analysis**

DNA, for the assessment of KRAS mutation test, was extracted from paraffin-embedded tumor tissue blocks (Qiagen, Hilden, Germany), which obtained from biopsy materials after primary tumor resection or biopsy. Polymerase chain reaction was performed via some extraction, incubation and amplifications cycles according to the manufacturer’s instructions. Tumor lesions with potential KRAS mutations in

**Codon 12:**
- + ___ Gly12Asp (GGT>GAC)
- + ___ Gly12Val (GGT>GCT)
- + ___ Gly12Cys (GGT>TGT)
- + ___ Gly12Ser (GGT>AGT)
- + ___ Gly12Ala (GGT>GCT)
- + ___ Gly12 Arg (GGT>CGT)
- + ___ Codon 12 mutation, not otherwise specified,

**Codon 13:**
- + ___ Gly13Asp (GGC>GAC)
- + ___ Gly13Arg (GGC>CAC)
- + ___ Gly13Cys (GGC>TGC)
- + ___ Gly13Ala (GGC>GCC)
- + ___ Gly13Val (GGC>GTC)
- + ___ Codon 13 mutation, not otherwise specified,

**Codon 59,**
**Codon 61:**
- + ___ Gln61Leu (CAA>CTA)
- + ___ Gln61His (CAA>CAC)
- + ___ Codon 61 mutation, not otherwise specified,

**Codon 617,**
**Codon 146:**
- + ___ Ala146Thr (GCA>ACA)
- + ___ Codon 146 mutation, not otherwise specified was detected.

**Statistical Analysis**

All data were analyzed using SPSS software for Windows (v21.0; IBM, Armonk, NY, USA). Data were expressed as mean and standard deviation, median (min-max), distribution frequencies and percentages, when appropriate. Normalization of data distribution was evaluated using Kolmogorov-Smirnov test. For variables that were not normally-distributed, comparison was performed using Mann-Whitney U and Kruskal-Wallis tests while correlation was evaluated using Pearson’s test. Categorical variables were evaluated using chi-square test. Survival rates were evaluated with Kaplan-Meier analysis. P values <0.05 were considered statistically significant.

**Results**

Out of 83 subjects with a diagnosis of colorectal cancer, 25 (30.1%) were female and 58 (69.9%) were male. Mean age was 59.8±11.3 years (range=35-81). Sixty-nine (83.1%) tumoral lesions were located in the left colon while 14 (16.9%) were located in the right colon. KRAS mutation was found in 54.2% (n=45) of patients. Thirty-eight (84.4%) of KRAS mutant colorectal tumors were left-sided while 7 (15.6%) were right-sided. Also, 18F-FDG uptake was observed in all primary lesions (n=83) and mean SUV\text{max} was estimated to be 21.1±9.2 (median=20.2, range=6.0-47.5). When clinical characteristics of the patients were considered along with 18F-FDG uptake, no statistically significant association was found between the mean SUV\text{max} in the group with patients younger than 50
years (19.6±6.2) (n=18) and the mean SUV\textsubscript{max} in the group with patients ≥50 years (21.5±9.8) (n=65) (p=0.436). Similarly, patient gender had no statistically significant impact on primary tumor mean SUV\textsubscript{max} (p=0.452) (Table 1). When subjects were evaluated for tumor localization, there was no difference between left-sided (21.2±8.6) and right-sided (20.4±11.6) tumors in terms of mean SUV\textsubscript{max} (p=0.768). Mean tumor SUV\textsubscript{max} of patients with KRAS mutation was 24.0±9.0 (Figure 1) while this value was calculated as 17.7±8.2 (Figure 2) in patients without mutation (wild type). Therefore, mean SUV\textsubscript{max} in subjects with KRAS mutation was significantly higher when compared to wild type (p=0.001) (Table 1).

According to the staging, 1 patient had stage II, 13 patients had stage III, and 69 patients had stage IV disease according to The American Joint Committee on Cancer TNM classification and staging system. Sixty-eight (81.9%) subjects were found to have locoregional nodal metastases at the time of diagnosis; 54 (79%) of these tumors were left-sided and 14 (21%) were right-sided. Twenty-six (31.3%) subjects had distant nodal metastases, 20 (77%) of which were left-sided and 6 (23%) of which were right-sided colon tumors. There was no difference between subjects with locoregional or distant nodal metastases and subjects without nodal metastases in terms of mean tumor SUV\textsubscript{max} (p=0.928 and 0.135, respectively) (Table 1). Initial PET/CT revealed organ metastases in 81.9% (n=68) of patients, while distant metastases developed later in follow-up in 18.1% (n=15). Similarly, there was no statistically significant difference between the group with distant metastases at diagnosis and the group with metastases developed in follow-up in terms of primary tumor mean SUV\textsubscript{max} (p=0.323). Distant organ metastases were most frequently observed in liver (47.0%, n=39), followed by lung (19.3%, n=16), peritoneum (8.4%, n=7) and liver + peritoneum (4.8%, n=4). Of patients, 20.5% (n=17) had multiorgan metastases.

Mean follow-up period of patients included was 35.5±18.9 months (range=3.8-73.4 months). Comparison of mean survival and clinical characteristics is presented in Table 2. According to this, mean survival time of patients with locoregional nodal metastasis and distant nodal metastasis (33.4±18.2 and 29.8±15.6 months, respectively) was significantly shorter than the survival time of patients without nodal metastases (42.9±21.2 months).}

### Table 1. The association between mean SUV\textsubscript{max} and clinical, histopathological features of patients

| Clinical variables          | n (%)          | SUV\textsubscript{max} (Mean ± SD) | p-value |
|----------------------------|----------------|----------------------------------|---------|
| **KRAS mutations**         |                |                                  |         |
| Mutant                     | 45 (54.2%)     | 24.0±9.0                         | 0.001*  |
| Wild                       | 38 (45.8%)     | 17.7±8.2                         |         |
| **Tumor localization**     |                |                                  |         |
| Left                       | 69 (83.1%)     | 21.2±8.6                         | 0.768   |
| Right                      | 14 (16.9%)     | 20.4±11.6                        |         |
| **Gender**                 |                |                                  |         |
| Female                     | 25 (30.1%)     | 19.9±7.5                         | 0.452   |
| Male                       | 58 (69.9%)     | 21.6±9.7                         |         |
| **Age**                    |                |                                  |         |
| <50                        | 18 (21.7%)     | 19.6±6.2                         | 0.436   |
| ≥50                        | 65 (78.3%)     | 21.5±9.8                         |         |
| **Locoregional nodal metastasis** |            |                                  |         |
| Absent                     | 15 (18.1%)     | 20.9±9.3                         | 0.928   |
| Present                    | 68 (81.9%)     | 21.1±9.1                         |         |
| **Distant nodal metastasis** |              |                                  |         |
| Absent                     | 57 (68.7%)     | 21.9±10.1                        | 0.135   |
| Present                    | 26 (31.3%)     | 19.2±6.3                         |         |
| **Distant organ metastasis** |              |                                  |         |
| Initially                   | 68 (81.9%)     | 20.6±9.1                         | 0.323   |
| Subsequently                | 15 (18.1%)     | 23.2±9.1                         |         |

* = p<0.05 statistically significant, SUV\textsubscript{max}: Maximum standardized uptake value, SD: Standard deviation.
without locoregional nodal metastasis and distant nodal metastasis (33.4±18.2 and 29.8±15.6 months, respectively) (p=0.037 and 0.046, respectively) (log rank=0.020 and 0.001, respectively) (Graph 1, 2). Also, mean survival time of patients with organ metastasis at diagnosis (33.4±19.0 months) was observed to be significantly shorter than patients who developed distant metastasis during follow-up (44.7±16.1 month) (p=0.037, log rank=0.023) (Graph 3). Mean survival was nearly statistically-significantly shorter in patients with tumors located to left colon (34.2±19.4) than in right colon (43.2±14.6) (p=0.059). KRAS mutation, age and sex were found to have no statistically significant influence on mean survival (p=0.136, 0.224 and 0.257, respectively).

Mean survival time after diagnosis was estimated to be 17.4±13.8 months (range=1.3-62.2 months). Mean overall survival after diagnosis of patients with KRAS-mutant and wild-type tumors was 18.3±16.3 and 16.7±11.5 months, respectively. Also, mean overall survival of patients with primary tumor located to left and right colon was 18.8±14.9 and 12.6±7.3 months, respectively with no statistically significant difference between groups (p values=0.818 and 0.391, respectively).

In our study, 52 patients (62.7%) received bevacizumab, 13 patients (15.7%) received cetuximab and 8 patients (9.6%) received panitumumab protocol as primary

![Figure 2. A 70-year-old male patient with wild type adenocarcinoma localized to sigmoid colon positron emission tomography, computed tomography, Fusion, maximum intensity projection. Red arrows show fluorodeoxyglucose uptake of the primary tumor. Primary tumor: SUV\textsubscript{max}: 11.5 dotted red arrows show hepatic metastases. SUV\textsubscript{max}: Maximum standardized uptake value, PET: Positron emission tomography, CT: Computed tomography, F: Fusion, MIP: Maximum intensity projection](image)

![Graph 1. Survival chart according to locoregional nodal involvement (log rank=0.020)](image)

Table 2. Comparison of patients' clinical/histopathological features and mean survival times

| Clinical variables                 | n (%)       | Survival (month) (Mean ± SD) | p-value |
|------------------------------------|-------------|-----------------------------|---------|
| KRAS mutations                     |             |                             |         |
| Mutant                             | 45 (54.2%)  | 32.6±19.8                   | 0.136   |
| Wild                               | 38 (%45.8%) | 38.8±17.5                   |         |
| Tumor localization                 |             |                             |         |
| Left                               | 69 (%83.1%) | 34.2±19.4                   | 0.059   |
| Right                              | 14 (%16.9%) | 43.2±14.6                   |         |
| Gender                             |             |                             |         |
| Female                             | 25 (%30.1%) | 39.3±19.9                   | 0.224   |
| Male                               | 58 (%69.9%) | 33.8±18.4                   |         |
| Age                                |             |                             |         |
| <50                                | 18 (%21.7%) | 40.0±21.1                   | 0.257   |
| ≥50                                | 65 (%78.3%) | 34.2±18.3                   |         |
| Locoregional nodal metastasis      |             |                             |         |
| Absent                             | 15 (%18.1%) | 44.6±20.3                   | 0.037*  |
| Present                            | 68 (%81.9%) | 33.4±18.2                   |         |
| Distant nodal metastasis           |             |                             |         |
| Absent                             | 57 (%68.7%) | 38.0±19.9                   | 0.046*  |
| Present                            | 26 (%31.3%) | 29.8±15.6                   |         |
| Distant organ metastasis           |             |                             |         |
| Initially                          | 68 (%81.9%) | 33.4±19.0                   | 0.037*  |
| Subsequently                       | 15 (%18.1%) | 44.7±16.1                   |         |

* = p<0.05 statistically significant, SD: Standard deviation
treatment. Of patients, 31.3% (n=26) showed progression and 6 of these (7.2%) received cetuximab, 17 (20.5%) received bevacizumab and 1 (1.2%) received aflibercept as second-line treatment. The presence of KRAS mutation and tumor localization were not significantly associated with progression (p=0.603 and 0.687, respectively). At the end of follow-up period, 57.8% of patients (n=48) were deceased. Among survivors, 7 patients (8.4%) were in remission, 20 patients were refractory and 8 were lost to follow-up (9.6%). The presence of KRAS mutation and tumor localization were not significantly associated with mortality (p=0.073 and 0.563, respectively).

**Discussion**

Despite the globally rising prevalence of colorectal cancers, recent developments in early diagnosis and treatment options have caused a decline in its incidence in especially advanced ages. However, the increase in the incidence of colorectal cancers in patients younger than 50 years is noteworthy (1,2,3,4). Because poor prognostic factors tend to accumulate in younger patients, predictive value of prognostic factors gain importance (9). Increased FDG uptake in 18F-FDG PET/CT imaging, which has been widely used in the diagnosis and staging of many malignancies including breast, gastric and lung carcinoma as well as colorectal cancer, is significantly associated with aggressive tumor pattern and poor prognosis (13,14,15,16).

Bundschuh et al. (17) evaluated 27 patients with locally advanced rectal cancer and reported that 18F-FDG PET/CT imaging has significant prognostic advantage in evaluating disease progression and provides important data in assessing treatment response and determining patients with high risk. In their study with 67 patients with colorectal cancer, Petersen et al. (18) stated the importance of 18F-FDG PET/CT imaging in staging and underlined that it was possible to change treatment strategy in approximately 30% of patients with the contribution of 18F-FDG PET/CT imaging. Besides these, the most important factors determining the prognosis in colorectal cancers are certainly the presence of nodal metastases and distant organ metastases. However, there are also prognostic factors specific to colorectal cancers which are sometimes controversial. The leading is KRAS mutations (8,9). Roth et al. (19) evaluated the prognostic effects of KRAS and BRAF mutations by extracting DNA from 1321 of 1404 specimens of colon cancer. The researcher concluded that KRAS mutation had no major prognostic value in patients with stage II and III colon cancer and did not influence survival. Ogino et al. (20) found similar results and reported that KRAS mutation had no effect on prognosis or survival. On the contrary, Lee et al. (21) found that KRAS mutations had negative prognostic effects on 437 patients with stage II and III colon cancer. Vogelaar et al. (22) pointed out the association between the presence of KRAS mutation and shorter survival. Similarly, Ribeiro et al. (23) evaluated 58 patients with metastatic colon adenocarcinoma and reported that KRAS mutation was significantly associated with lymph node metastasis and organ metastasis when evaluated together with CD44 and CD166 expression. As the literature data indicate, findings about KRAS are quite contradictory. In our study, we observed that survival times shortened significantly with locoregional and distant nodal metastases.
metastasis and the presence of distant organ metastasis at diagnosis while KRAS mutation had no statistically significant effect on mean survival. Also, the presence of KRAS mutation was found to have no significant impact on patients who were deceased or showed progression after treatment. However, when KRAS mutation was assessed together with FDG uptake pattern, mean tumor SUV\textsubscript{max} was observed to increase significantly in subjects with KRAS mutation. Therefore, considering that increased FDG uptake is associated with aggressive tumor characteristics and negative prognostic effect, increased SUV\textsubscript{max} in the presence of KRAS mutations was interpreted as a poor prognostic factor.

Another controversial topic in prognostic factor assessment for colon cancer is tumor side. Embryologic, histological, genetic and immunological differences of the right and left colon provide basis for these discussion. Certain studies in the literature could not define any difference between the right and left colon that can affect survival, while others reported the left colon to be associated with higher survival (10). Karim et al. (24) evaluated 6365 patients who were diagnosed with early stage colon cancer between 2002 and 2008 and concluded that tumor side had no significant association with overall survival or cancer-specific survival. In contrast, Petrelli et al. (25) conducted a meta-analysis that includes 66 studies with 1,437,846 patients and reported that tumors localized to left colon had significantly lower risk of death and this was independent of stage, ethnicity and adjuvant chemotherapy. Similarly, in the study by Ulanja et al. (10) that included 163,986 patients with colon cancer with the help of the “Surveillance, Epidemiology, and End Results” database, the researchers reported that 52.3% of tumors were localized in the right colon and 47.7% were in the left colon while left colon cancer was significantly associated with better survival. In our study, 83.1% of tumoral lesions were left-sided while 16.9% were right-sided. We found no statistically significant difference between tumors localized to right or left colon both in terms of FDG uptake and survival. Also, tumor localization and the presence of KRAS mutation had no statistically significant impact on mortality. However, we think that our prognostic evaluation using both 18F-FDG PET/CT imaging modality and the presence of KRAS mutation may have a predictive value.

Conclusion

In conclusion, side of tumor in patients with colorectal cancer was not found to have significant impact on prognosis in our study. On the other hand, we observed an association between the presence of KRAS mutation and increased FDG uptake in the primary tumor. We think that this association may have a predictive value for poor prognosis and our data may contribute to patient management especially in this subgroup.

Ethics

Ethics Committee Approval: The study has been approved by the Istanbul Training and Research Hospital Local Ethics Committee (no: 2018/1228).

Informed Consent: Consent form was filled out by all participants.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: E.Ç., N.D., Concept: E.A., T.A., T.F.Ç., Design: E.A., Data Collection or Processing: E.A., R.U.G., Analysis or Interpretation: E.A., T.F.Ç., Literature Search: T.A., E.A., Writing: E.A., T.A., T.F.Ç.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Stewart BW, WC. World cancer report 2014. Available at: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. Accessed June 8, 2019.
3. Pan P, Yu J, Wang LS. Colon cancer: what we eat. Surg Oncol Clin N Am 2018;27:243-267.
4. World Cancer Research Fund/American Institute for Cancer Research. Continuous update project report. Food, nutrition, physical activity, and the prevention of colorectal cancer. Available at: http://www.aicr.org/continuousupdate-project/reports/Colorectal-Cancer-2011-Report.pdf. Accessed July 2, 2019.
5. Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. 2018;11:267-276.
6. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg 2013;148:747-754.
7. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM,
Settleman J. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-608.

8. Brito H, Martins AC, Lavrado J, Mendes E, Francisco AP, Santos SA, Ohnmacht SA, Kim NS, Rodrigues CM, Moreira R, Neidle S. Targeting KRAS oncogene in colon cancer cells with 7-carboxylate indolo[3,2-b]quinoline tri-alkylamine derivatives. PLoS One 2015;10:e0126891.

9. Graziosi L, Elisabetta M, Rebonato A, Donini A. Preoperative Serum Markers Prognostic Evaluation in Colon Cancer Patients. J Cancer Sci Ther 2018;10:22-26.

10. Ulanja MB, Rishi M, Beutler BD, Sharma M, Patterson DR, Gullapalli N, Ambika S. Colon Cancer Sidedness, Presentation, and Survival at Different Stages. J Oncol 2019;2019:4315032.

11. Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil BH, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). http://meetinglibrary.asco.org/record/123617/abstract. Presented June 25, 2016. Accessed May 26, 2017.

12. Puppa G, Sonzogni A, Colombo R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010;134:837-852.

13. Groheux D, Cochet A, Humbert O, et al. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med 2016;57:17-26.

14. Wu Z, Zhao J, Gao P et al. Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis. BMC Cancer 2017;17:275.

15. Aogi K, Kadoya T, Sugawara Y, et al. Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat 2015;150:209-217.

16. Ben-Haim S, El P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009;50:88-99.

17. Bundschuh RA, Dinges J, Neumann L, Seyfried M, Zsotér N, Papp L, Rosenberg R, Becker K, Astner ST, Henninger M, Herrmann K. Textural parameters of tumor heterogeneity in 18F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer. J Nucl Med 2014;55:891-897.

18. Petersen RK, Hess S, Alavi A, Carlsen PFH. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging 2014;4(5):471-482.

19. Roth AD, Teijar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmann B, Bodoky G, Barone C, Araneda E. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60:00 trial. J Clin Oncol 2010;28:466-474.

20. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hentel A, Benson AB. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.

21. Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim T, Oh DY, Im SA. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol 2015;22:187-194.

22. Vogelaar FI, van Erning FN, Reimers MS, van der Linden H, Bruij H, van den Brule AJ, Bosscha K. The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med 2015;21:1038-1046.

23. Ribeiro KB, da Silva Zanetti J, Ribeiro-Silva A, Rapatoni L, de Oliveira HE, da Cunha Tirapelli DP, Garcia SB, Feres O, da Rocha JJ, Penia FM. KRAS mutation associated with CD44/CD166 immunoeexpression as predictors of worse outcome in metastatic colonic cancer. Cancer Biomark 2016;16:513-521.

24. Karim S, Brennan K, Nanji S, Berry SR, Booth CM. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol 2017;3:1386-1392.

25. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 2017;3:211-219.